CA
NZ
UK
AU
IND
US
…
BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells. It develops programs relate to the treatment of disc/spine disease and metabolic disorders. The company's products pipeline comprises BRTX-100, a lead cell therapy candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, as well as used for the non-surgical treatment of painful lumbosacral disc disorders or as a complimentary therapeutic to a surgical procedure; and ThermoStem, a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. It also operates a commercial biocosmeceutical platform. In addition, the company provides investigational curved needle device to deliver cells and/or other therapeutic products or material to the spine and discs, and other parts of the body. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. is headquartered in Melville, New York.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
BioRestorative Therapies, Inc. is a development-stage company focused on regenerative medicine and cell-based therapies for tissue repair and related conditions. Long-term growth drivers include progress in clinical development, regulatory approvals, partnerships or licensing and scaling cell manufacturing, which may benefit commercial adoption. Investors may find exposure to regenerative medicine and upside from program advancement of interest.
Key investment risks include program failures, significant financing needs, manufacturing and regulatory hurdles that could delay development or dilute shareholders.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -14.24M | -8.98M | -10.42M | -18.49M | -44.30M |
| Net income | -14.24M | -8.98M | -10.42M | -18.02M | -29.94M |
| Selling general administrative | 5.89M | 6.58M | 11.33M | 15.58M | 25.61M |
| Selling and marketing expenses | - | 0.17M | 0.17M | - | 0.01M |
| Gross profit | 0.34M | 0.37M | 0.15M | 0.12M | 0.05M |
| Reconciled depreciation | 0.21M | 0.19M | 0.15M | 0.12M | 0.09M |
| Ebit | -15.65M | -11.56M | -15.14M | -18.97M | -26.31M |
| Ebitda | -15.44M | -11.37M | -14.97M | -18.99M | -42.40M |
| Depreciation and amortization | 0.21M | 0.19M | 0.17M | -0.02M | -16.09M |
| Operating income | -15.65M | -11.56M | -15.22M | -18.97M | -26.31M |
| Other operating expenses | 16.01M | 11.96M | 15.37M | 18.98M | 26.35M |
| Interest expense | - | - | - | 0.01M | 1.82M |
| Interest income | 0.27M | 0.62M | 0.55M | - | - |
| Net interest income | 0.27M | 0.62M | 0.29M | 0.01M | -1.82M |
| Income tax expense | - | - | -0.00M | -0.48M | -14.36M |
| Total revenue | 0.36M | 0.40M | 0.15M | 0.12M | 0.05M |
| Total operating expenses | 15.98M | 11.93M | 15.37M | 18.98M | 26.35M |
| Cost of revenue | 0.02M | 0.03M | 0.17M | - | - |
| Total other income expense net | 1.41M | 2.58M | 4.80M | 0.48M | -18.00M |
| Net income from continuing ops | -14.24M | -8.98M | -15.94M | -18.49M | -44.30M |
| Net income applicable to common shares | - | - | - | -18.49M | -44.30M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 4.08M | 12.28M | 12.61M | 16.43M | 22.45M |
| Intangible assets | 0.53M | 0.62M | 0.71M | 0.80M | 0.59M |
| Other current assets | 0.17M | 0.22M | 0.31M | 0.36M | 0.44M |
| Total liab | 3.72M | 3.75M | 1.06M | 0.60M | 0.86M |
| Total stockholder equity | 0.36M | 8.53M | 11.55M | 15.83M | 21.60M |
| Other current liab | 2.38M | 3.27M | 0.71M | 0.13M | 0.13M |
| Common stock | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Capital stock | 0.01M | 0.01M | - | 0.02M | 0.02M |
| Retained earnings | -169.92M | -155.68M | -167.06M | -152.64M | -134.15M |
| Cash | 1.51M | 0.55M | 0.88M | 1.68M | 21.03M |
| Total current liabilities | 3.72M | 3.75M | 1.06M | 0.44M | 0.36M |
| Current deferred revenue | - | - | 0.00M | - | - |
| Net debt | -1.51M | -0.55M | -0.72M | -1.37M | -20.36M |
| Short term debt | - | 0.32M | 0.16M | 0.14M | 0.18M |
| Short long term debt | - | - | - | - | 0.06M |
| Short long term debt total | - | 0.16M | 0.16M | 0.30M | 0.67M |
| Other stockholder equity | 170.26M | 164.20M | 178.59M | 168.46M | 155.73M |
| Property plant equipment | - | - | - | 0.50M | 0.40M |
| Total current assets | 3.14M | 11.14M | 11.39M | 15.13M | 21.47M |
| Net tangible assets | - | - | - | 15.01M | 20.99M |
| Short term investments | 1.44M | 10.18M | 10.18M | 13.07M | - |
| Net receivables | 0.02M | 0.19M | 0.02M | 0.02M | 0.01M |
| Long term debt | - | - | - | - | 0.19M |
| Inventory | - | - | 0.00M | - | - |
| Accounts payable | 1.34M | 0.48M | 0.19M | 0.17M | 0.05M |
| Accumulated other comprehensive income | - | - | 0.00M | - | - |
| Non currrent assets other | 0.05M | 0.15M | - | - | - |
| Non current assets total | 0.94M | 1.14M | 1.22M | 1.31M | 0.99M |
| Capital lease obligations | - | 0.00M | - | 0.30M | 0.42M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | 9.01M | 0.51M | -0.17M | -13.48M | -0.03M |
| Change to liabilities | - | - | - | 0.12M | -0.07M |
| Total cashflows from investing activities | 8.90M | 0.51M | 3.25M | -13.48M | -0.03M |
| Net borrowings | - | - | - | - | 0.25M |
| Total cash from financing activities | 2.85M | 7.38M | 2.35M | 0.00M | 21.32M |
| Change to operating activities | - | - | - | -0.09M | 0.38M |
| Net income | -14.24M | -8.98M | -10.42M | -18.49M | -44.30M |
| Change in cash | 0.96M | -0.34M | -0.83M | -19.35M | 17.96M |
| Begin period cash flow | 0.55M | 0.88M | 1.71M | 21.03M | 3.06M |
| End period cash flow | 1.51M | 0.55M | 0.88M | 1.68M | 21.03M |
| Total cash from operating activities | -10.79M | -8.23M | -6.43M | -5.87M | -3.33M |
| Issuance of capital stock | 3.10M | 0.00M | 2.27M | 0.00M | 21.07M |
| Depreciation | 0.21M | 0.19M | 0.17M | 0.12M | 0.09M |
| Other cashflows from investing activities | -0.12M | -0.11M | - | - | - |
| Dividends paid | 0.27M | 0.62M | 0.57M | - | - |
| Change to inventory | - | - | -0.00M | - | - |
| Change to account receivables | 0.17M | -0.17M | -0.00M | -0.01M | 0.01M |
| Other cashflows from financing activities | 0.17M | 7.38M | 2.35M | -13.48M | 0.25M |
| Change to netincome | - | - | - | 12.49M | 39.43M |
| Capital expenditures | 0.12M | 0.11M | 0.17M | 0.44M | 0.03M |
| Change in working capital | 1.31M | 0.03M | 0.52M | 0.01M | 0.32M |
| Stock based compensation | 3.33M | 2.81M | 7.78M | 12.61M | 23.11M |
| Other non cash items | -1.39M | -2.28M | -4.48M | -0.12M | 1.27M |
| Free cash flow | -10.91M | -8.34M | -6.60M | -6.31M | -3.36M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| BRTX BioRestorative Therapies Inc |
0.15 10.49% |
1.58 | - | - | 16.86 | 19.18 | 1.05 | 0.13 |
| NVO Novo Nordisk A/S |
0.85 2.22% |
39.14 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
10.31 1.95% |
540.00 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
5.50 0.68% |
818.77 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
790.15 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells. It develops programs relate to the treatment of disc/spine disease and metabolic disorders. The company's products pipeline comprises BRTX-100, a lead cell therapy candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, as well as used for the non-surgical treatment of painful lumbosacral disc disorders or as a complimentary therapeutic to a surgical procedure; and ThermoStem, a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. It also operates a commercial biocosmeceutical platform. In addition, the company provides investigational curved needle device to deliver cells and/or other therapeutic products or material to the spine and discs, and other parts of the body. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. is headquartered in Melville, New York.
| Name | Title | Year Born |
|---|---|---|
| Mr. Lance Alstodt | Chairman, Pres & CEO | 1971 |
| Mr. Francisco J. Silva | Chief Scientist, VP of R&D, Sec. and Director | 1975 |
| Mr. Robert Eugene Kristal | Chief Financial Officer | 1968 |
| Mr. Robert Paccasassi | VP of Quality Assurance & Regulatory Compliance | 1969 |
| Dr. Wayne J. Olan M.D. | Clinical Director of Regenerative Disc & Spine Program and Member of Scientific Advisory Board | NA |
| Mr. Lance Alstodt | Chairman of the Board, President & CEO | 1971 |
| Mr. Francisco J. Silva | Chief Scientist, VP of Research & Development, Secretary and Director | 1975 |
| Mr. Robert Paccasassi | Vice President of Quality Assurance & Regulatory Compliance | 1969 |
| Mr. Francisco J. Silva | VP of Research & Development, Secretary and Director | 1975 |
| Ms. Crystal Romano | Head of Global Commercial Operations | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-0.52%
Communication Services
+0.32%
Consumer Cyclical
+1.01%
Consumer Defensive
+0.00%
Energy
+0.01%
Financial Services
+0.62%
Financials
-2.62%
Healthcare
+0.51%
Industrials
+0.71%
Real Estate
+0.72%
Technology
-0.46%
Utilities
+0.54%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...